BlogTalkRadio uses cookies. By using our services, you're agreeing to our Cookies Policy. Got it

Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Myeloma Crowd Radio: Irene Ghobrial, MD, Dana Farber Cancer Institute Impact

  • Broadcast in Health
Myeloma Crowd Radio

Myeloma Crowd Radio

×  

Follow This Show

If you liked this show, you should follow Myeloma Crowd Radio.
h:539173
s:11861407
archived

Dr. Irene Ghobrial joins Myeloma Crowd Radio to share a study to identify discoveries that could potentially inform COVID-19 treatment decisions and prevention policies in the IMPACT study. Myeloma patients are known to be immunocompromised and may be at higher risk for poor outcomes. 

IMPACT is a study to identify the prevalence and unique characteristics of COVID-19 in individuals with precursor conditions to hematologic malignancies and in healthy populations. It is enrolling individuals nationwide who are enrolled in the PCROWD and PROMISE studies.

All participants enrolled in IMPACT are screened using a blood test for active SARS-CoV-2 and/or antibodies. Participants are then followed and undergo additional blood collection and testing over a one-year period. The overall goal of IMPACT is to understand the short- and long-term impact of COVID-19 on the immune system of healthy individuals and individuals with underlying immune dysregulation.

Thanks to our episode sponsor, Bristol Myers Squibb

Comments